Free Trial
NASDAQ:SCNI

Scinai Immunotherapeutics (SCNI) Stock Price, News & Analysis

Scinai Immunotherapeutics logo
$1.40 -0.06 (-4.11%)
Closing price 10/17/2025 03:59 PM Eastern
Extended Trading
$1.40 0.00 (-0.29%)
As of 10/17/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Scinai Immunotherapeutics Stock (NASDAQ:SCNI)

Advanced

Key Stats

Today's Range
$1.39
$1.48
50-Day Range
$1.20
$1.82
52-Week Range
$1.20
$6.18
Volume
26,366 shs
Average Volume
109,840 shs
Market Capitalization
$4.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

Scinai Immunotherapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
26th Percentile Overall Score

SCNI MarketRank™: 

Scinai Immunotherapeutics scored higher than 26% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Scinai Immunotherapeutics is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Scinai Immunotherapeutics is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Scinai Immunotherapeutics has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Scinai Immunotherapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.81% of the outstanding shares of Scinai Immunotherapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Scinai Immunotherapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Scinai Immunotherapeutics has recently decreased by 71.32%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Scinai Immunotherapeutics does not currently pay a dividend.

  • Dividend Growth

    Scinai Immunotherapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.81% of the outstanding shares of Scinai Immunotherapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Scinai Immunotherapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Scinai Immunotherapeutics has recently decreased by 71.32%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Scinai Immunotherapeutics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Scinai Immunotherapeutics this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Scinai Immunotherapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.03% of the stock of Scinai Immunotherapeutics is held by insiders.

  • Percentage Held by Institutions

    58.41% of the stock of Scinai Immunotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Scinai Immunotherapeutics' insider trading history.
Receive SCNI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scinai Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SCNI Stock News Headlines

Move $1,000 into this stock before Nov 6
The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff, as the world's biggest car firm prepares to launch a "mind blowing" new product. It has nothing to do with EVs, or self-driving cars. In fact, it's not a car at all...tc pixel
See More Headlines

SCNI Stock Analysis - Frequently Asked Questions

Scinai Immunotherapeutics' stock was trading at $3.35 at the beginning of 2025. Since then, SCNI shares have decreased by 58.2% and is now trading at $1.40.

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) posted its earnings results on Wednesday, May, 7th. The company reported ($10.40) earnings per share for the quarter. The company earned $0.21 million during the quarter.

Shares of Scinai Immunotherapeutics reverse split on the morning of Tuesday, May 21st 2024.The 1-10 reverse split was announced on Tuesday, May 21st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 21st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of SCNI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Scinai Immunotherapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET), AppLovin (APP), e.l.f. Beauty (ELF) and Disc Medicine (IRON).

Company Calendar

Last Earnings
5/07/2025
Today
10/20/2025
Next Earnings (Estimated)
11/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SCNI
Previous Symbol
NASDAQ:SCNI
CIK
1611747
Employees
20
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.13
Current Ratio
0.71
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$660 thousand
Price / Sales
6.77
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.10 per share
Price / Book
0.27

Miscellaneous

Outstanding Shares
3,190,000
Free Float
2,996,000
Market Cap
$4.47 million
Optionable
Not Optionable
Beta
1.90
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:SCNI) was last updated on 10/20/2025 by MarketBeat.com Staff
From Our Partners